Literature DB >> 17219394

Serum cytokine levels in response to hepatic cryoablation.

Shinji Osada1, Hisashi Imai, Hiroyuki Tomita, Yasuharu Tokuyama, Naoki Okumura, Nobuhisa Matsuhashi, Fumio Sakashita, Kenichi Nonaka.   

Abstract

BACKGROUND AND OBJECTIVES: Cryogenic treatment sometimes stimulates the immune system by releasing intracellular antigens. We evaluated anti-tumor immune response by analyzing alterations in serum cytokine levels.
METHODS: Percutaneous cryosurgery was performed in 13 patients with unresectable tumors. Serum levels of interleukin (IL) -4, -6, and -10, tumor necrosis factor (TNF)-alpha, and interferon (IFN)-gamma were measured by enzyme-linked immunosorbent assay (ELISA). The Th1/Th2 ratio was estimated from the IFN-gamma/IL-4 ratio.
RESULTS: Levels of serum factors in the immune reaction (IR) group, in which tumor necrosis was identified not only in the treated area but also away from the treated area, were compared with those in the local effect (LE) group. Serum amyloid A (SAA), C-reactive protein (CRP), and IL-6 levels were increased in both groups after three treatments. The serum IL-10 level tended to increase with the number of treatments. Pretreatment IL-10 levels in the LE group were significantly greater than those in the IR group, and the maximum value in the LE group (59.5 +/- 13.2 pg/ml) was greater than that in the IR group (47.0 +/- 15.0 pg/ml). The TNF-alpha level was increased in the IR group. Pretreatment TNF-alpha levels and maximum levels in response to treatment were significantly greater in the IR group than in the LE group (P = 0.0313). The Th1/Th2 ratio was increased in the IR group, and the maximum ratio was significantly greater in the IR group than in the LE group.
CONCLUSION: It might be possible to evaluate the appearance of immune responses to cryosurgery by monitoring serum cytokine levels. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17219394     DOI: 10.1002/jso.20712

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  24 in total

Review 1.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Cryoimmunology for malignant bone and soft-tissue tumors.

Authors:  Hideji Nishida; Norio Yamamoto; Yoshikazu Tanzawa; Hiroyuki Tsuchiya
Journal:  Int J Clin Oncol       Date:  2011-03-12       Impact factor: 3.402

3.  Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study.

Authors:  Archana Thakur; Peter Littrup; Elyse N Paul; Barbara Adam; Lance K Heilbrun; Lawrence G Lum
Journal:  J Immunother       Date:  2011-06       Impact factor: 4.456

4.  Tumour seeding after percutaneous cryoablation for hepatocellular carcinoma.

Authors:  Chun-Ping Wang; Hong Wang; Jian-Hui Qu; Yin-Ying Lu; Wen-Lin Bai; Zheng Dong; Xu-Dong Gao; Guang-Hua Rong; Zhen Zeng; Yong-Ping Yang
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

5.  Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma.

Authors:  Lin Zhou; Jun-Liang Fu; Yin-Ying Lu; Bao-Yun Fu; Chun-Ping Wang; Lin-Jing An; Xin-Zhen Wang; Zhen Zeng; Chun-Bao Zhou; Yong-Ping Yang; Fu-Sheng Wang
Journal:  J Gastroenterol       Date:  2010-04-22       Impact factor: 7.527

6.  Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases.

Authors:  Matias E Valsecchi; Mizue Terai; David J Eschelman; Carin F Gonsalves; Inna Chervoneva; Jerry A Shields; Carol L Shields; Akira Yamamoto; Kevin L Sullivan; MaryAnn Laudadio; David Berd; Michael J Mastrangelo; Takami Sato
Journal:  J Vasc Interv Radiol       Date:  2015-02-09       Impact factor: 3.464

7.  Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.

Authors:  Yongping Yang; Yinying Lu; Chunping Wang; Wenlin Bai; Jianhui Qu; Yan Chen; Xiujuan Chang; Linjing An; Lin Zhou; Zhen Zeng; Min Lou; Jiyun Lv
Journal:  Exp Ther Med       Date:  2011-12-01       Impact factor: 2.447

8.  Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer.

Authors:  Dinesh Chandra; Arthee Jahangir; Francois Cornelis; Klara Rombauts; Lydie Meheus; Cheryl L Jorcyk; Claudia Gravekamp
Journal:  Oncoimmunology       Date:  2015-05-29       Impact factor: 8.110

Review 9.  Enhancing immune responses to tumor-associated antigens.

Authors:  Jack P Higgins; Michael B Bernstein; James W Hodge
Journal:  Cancer Biol Ther       Date:  2009-08-01       Impact factor: 4.742

10.  Clinical outcome, proteome kinetics and angiogenic factors in serum after thermoablation of colorectal liver metastases.

Authors:  Marieke W J L A E Wertenbroek; Marianne Schepers; Hannetta J Kamminga-Rasker; Jan T Bottema; Anneke C Muller Kobold; Han Roelofsen; Koert P de Jong
Journal:  BMC Cancer       Date:  2013-05-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.